489OOsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. (25th November 2018) - Planchard, D; Boyer, M; Lee, J-S; Dechaphunkul, A; Cheema, P; Takahashi, T; Todd, A; McKeown, A; Rukazenkov, Y; Ohe, Y